CAPTRUST Financial Advisors
CRNX icon

CAPTRUST Financial Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,192
Closed -$22K – 2478
2022
Q2 		$22K Hold
1,192
– – ﹤0.01% 3310
2022
Q1 		$26K Hold
1,192
– – ﹤0.01% 3227
2021
Q4 		$34K Buy
1,192
+1,169
+5,083% +$28.8K ﹤0.01% 2939
2021
Q3 		$0 Hold
23
– – ﹤0.01% 4660
2021
Q2 		$0 Hold
23
– – ﹤0.01% 4537
2021
Q1 		$0 Buy
+23
New +$356 ﹤0.01% 4390

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CAPTRUST Financial Advisors's CRNX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2022, closing a stake of 1,192 shares — an estimated $22K sold.

CAPTRUST Financial Advisors first reported a position in CRNX in Q1 2021 and held it in 6 quarters. The position peaked at $34K in Q4 2021. 122 funds tracked by Wall St. Rank hold CRNX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Crinetics Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,192 Crinetics Pharmaceuticals shares in Q3 2022, an estimated $22K.
  • CAPTRUST Financial Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's Crinetics Pharmaceuticals position peaked at $34K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.